Nestle India Faces FSSAI Legal Action Over Infant Nutrition Products
Nestle India FSSAI legal action has been initiated after the Food Safety and Standards Authority of India (FSSAI) raised concerns over alleged regulatory non-compliance involving the company’s infant nutrition products. The action covers promotional claims associated with NAN Excella Pro Stage 1 and Lactogen Pro 1, while a separate case relates to the nutritional composition of another follow-up formula product.
According to FSSAI, the regulator examined the products and promotional material available on e-commerce platforms before initiating three separate adjudication proceedings against Nestle India. The cases involve both promotional claims and a laboratory finding concerning biotin levels in a follow-up formula.
Nestle India, meanwhile, has said that its infant nutrition products comply with applicable regulations and that the labels for NAN Excella Pro and Lactogen Pro had received approval from an FSSAI expert committee.
FSSAI Initiates Three Adjudication Cases
The Nestle India FSSAI legal action involves three separate adjudication cases.
Two of the cases concern claims made in connection with NAN Excella Pro Stage 1 and Lactogen Pro 1. The third case concerns a follow-up formula sample that FSSAI said did not meet the prescribed nutritional requirement for biotin during laboratory testing.
FSSAI said it reviewed product information and promotional material available through e-commerce platforms as part of its proceedings.
The regulator’s action highlights the additional scrutiny applied to infant nutrition products, where product composition, labelling and promotional claims are governed by specific food-safety and infant-food regulations.
What FSSAI Flagged in NAN Excella Pro Stage 1
In the case of NAN Excella Pro Stage 1, FSSAI raised concerns about promotional claims relating to five human milk oligosaccharides (5 HMOs) and whey protein.
Human milk oligosaccharides, commonly known as HMOs, are complex carbohydrates naturally found in breast milk. They are also used as ingredients in some infant nutrition products.
FSSAI’s proceedings concern how such product attributes were presented in promotional material. The regulator has alleged that the claims did not comply with applicable requirements governing infant food promotion.
Importantly, the legal action concerns the regulator’s allegations and does not by itself establish a final finding of liability. The adjudication process will determine the outcome of the proceedings.
Lactogen Pro 1 Claim Also Under Scrutiny
The second case involves Lactogen Pro 1.
FSSAI flagged a promotional claim relating to whey protein being easy to digest. The regulator has raised the issue under rules governing claims and promotion of infant nutrition products.
Infant formula advertising and promotional communications are subject to tighter restrictions than many other food categories because of the regulatory emphasis on infant nutrition and the promotion of breastfeeding.
The proceedings therefore focus on whether the claims used in the marketing and presentation of the product complied with the relevant legal framework.
Separate Biotin Issue Involves Follow-Up Formula
The third case is different from the promotional-claim issues involving NAN Excella Pro and Lactogen Pro.
FSSAI said a sample of a follow-up formula manufactured by Nestle India was found to contain biotin at a level that did not meet the prescribed requirement during laboratory analysis. The sample was subsequently reanalysed, with the referral laboratory also finding that it did not conform to the required biotin standard.
Biotin, also known as vitamin B7, is a water-soluble vitamin involved in several metabolic processes.
The laboratory finding forms the basis of a separate regulatory proceeding against the company.
Nestle India Says Products Comply With Regulations
Nestle India has disputed the suggestion that its products are non-compliant.
Following the FSSAI action, the company said that its infant nutrition products remain compliant with applicable regulations. Nestle also stated that NAN Excella Pro and Lactogen Pro and their labels had been approved by an FSSAI expert committee.
The company has also said that it will continue to cooperate with the food regulator.
This means the matter currently involves competing positions: FSSAI has initiated adjudication proceedings based on its regulatory findings, while Nestle maintains that the products and relevant labels comply with the applicable requirements.
Why Infant Formula Regulations Are Strict
Infant nutrition products operate under a highly regulated framework in India.
Rules governing infant foods cover areas such as nutritional composition, labelling and promotional claims. The regulatory framework is designed to ensure that information provided to parents and caregivers is accurate and does not undermine public-health objectives surrounding infant feeding.
For this reason, claims involving nutritional ingredients or product characteristics can face greater regulatory scrutiny than similar claims made for ordinary food products.
The current FSSAI proceedings involving Nestle demonstrate how regulators can examine not only the physical composition of infant products but also the way those products are presented to consumers.
E-Commerce Platforms Also Under Regulatory Focus
One notable aspect of the proceedings is FSSAI’s examination of promotional material available on e-commerce platforms.
The regulator said it reviewed product information and promotional material available online as part of its proceedings.
This reflects the growing importance of digital marketplaces in the sale of packaged food and nutrition products.
Product descriptions, marketing claims and other information displayed online can influence purchasing decisions, making regulatory oversight of digital product listings increasingly relevant.
For companies operating in highly regulated categories, compliance therefore extends beyond physical packaging and traditional advertising channels.
What the Legal Action Means for Nestle India
The FSSAI proceedings place additional regulatory attention on Nestle India’s infant nutrition business.
The company now faces three separate adjudication cases related to the infant nutrition products and issues identified by the regulator.
However, the initiation of legal proceedings should be distinguished from a final adjudication outcome. The cases remain part of the regulatory process, and the company has stated that it complies with applicable regulations.
The final consequences, if any, will depend on the outcome of the proceedings and the findings of the relevant authorities.
Impact on India’s Infant Food Industry
The case also highlights the importance of regulatory compliance across India’s infant food sector.
Manufacturers of infant nutrition products must comply with requirements covering nutritional standards, labelling and marketing. The sector is particularly sensitive because consumers include infants and young children, while purchasing decisions are often made by parents and caregivers.
Regulatory scrutiny can therefore extend across the entire product lifecycle, from formulation and laboratory testing to packaging and online promotion.
The FSSAI action against Nestle is likely to keep attention focused on how infant nutrition products are labelled and marketed in India.
What Happens Next?
The three cases will proceed through the relevant adjudication process.
For NAN Excella Pro Stage 1 and Lactogen Pro 1, the proceedings will address the promotional claims identified by FSSAI. The separate follow-up formula case will concern the reported non-conforming biotin level.
Nestle India is expected to present its position during the regulatory proceedings. The company has already stated that its products comply with applicable regulations and that the relevant labels had received expert committee approval.
The eventual outcome will depend on the regulatory and legal process.
Looking Ahead
The Nestle India FSSAI legal action puts the spotlight on regulatory compliance in India’s infant nutrition market. FSSAI has initiated three adjudication cases involving promotional claims associated with NAN Excella Pro Stage 1 and Lactogen Pro 1, along with a separate laboratory finding concerning the biotin content of a follow-up formula.
Nestle India has maintained that its products comply with applicable regulations and has said it will continue working with FSSAI.
The case also highlights the importance of accurate product claims, nutritional standards and digital marketing compliance in the infant food sector. As the adjudication proceedings continue, the final outcome will determine whether further regulatory action is warranted.
Frequently Asked Questions
1. What is the Nestle India FSSAI legal action about?
FSSAI has initiated three adjudication cases involving Nestle India’s infant nutrition products. Two concern promotional claims, while another relates to the reported biotin content of a follow-up formula sample.
2. Which Nestle products are involved?
The proceedings include NAN Excella Pro Stage 1, Lactogen Pro 1 and a separate follow-up formula manufactured by Nestle India.
3. What did FSSAI flag about NAN Excella Pro Stage 1?
FSSAI raised concerns about promotional claims relating to 5 HMOs and whey protein.
4. What issue did FSSAI identify with Lactogen Pro 1?
The regulator flagged a claim relating to whey protein being easy to digest in promotional material associated with Lactogen Pro 1.
5. What is the biotin issue involving Nestle?
FSSAI said a sample of a Nestle follow-up formula did not meet the prescribed biotin requirement during laboratory testing. A subsequent referral laboratory analysis also found the sample non-conforming.
6. What has Nestle India said about the allegations?
Nestle India has said its infant nutrition products comply with applicable regulations. It also stated that the NAN Excella Pro and Lactogen Pro products and their labels had been approved by an FSSAI expert committee.
7. Does the FSSAI action mean Nestle has been found guilty?
No. The regulator has initiated adjudication proceedings. The final outcome will depend on the relevant legal and regulatory process.
8. Why are infant formula products heavily regulated?
Infant nutrition products are subject to specific requirements covering composition, labelling and promotion because of their role in infant feeding and the need to protect consumers from misleading information.
9. Did FSSAI examine online product information?
Yes. FSSAI said it examined the products and promotional material available on e-commerce platforms as part of its proceedings.
10. What happens next in the Nestle FSSAI case?
The three adjudication proceedings will continue, with the regulator and company presenting their respective positions. The final outcome will determine whether additional regulatory measures or penalties follow.
